Schönlein–Henochn.
/ˌʃəːnlʌɪnˈhɛnɒx/, /ˌʃəːnlʌɪnˈhɛnɒk/, /ˌʃəːnlʌɪnˈhiːnɒx/, /ˌʃəːnlʌɪnˈhiːnɒk/, U.S. /ˌʃənlaɪnˈhɛˌnɑk/, /ˌʃoʊnlaɪnˈhɛˌnɑk/, /ˌʃənlaɪnˈhɛnək/, /ˌʃoʊnlaɪnˈhɛnək/, /ˌʃənlaɪnˈhiˌnɑk/, /ˌʃoʊnlaɪnˈhiˌnɑk/, /ˌʃənlaɪnˈhinək/, /ˌʃoʊnlaɪnˈhinək/ Medicine. Now somewhat rare.
attributive and in the genitive, esp. in Schönlein–Henoch purpura. Designating a disorder occurring mainly in children, characterized by the presence of a palpable purpuric rash typically accompanied by a combination of other findings including pain and swelling of the joints, colicky abdominal pain, and blood or protein in the urine; = Henoch–Schönlein n.
ΚΠ
1922 Internat. Med. & Surg. Surv. 4 No. 1. v. 1175 The author does not separate Schönlein-Henoch's purpura as ‘anaphylactoid purpura’ from Werlhof's purpura.
1953 Lancet 8 Aug. 282/2 Treatment with corticotrophin and cortisone has also been tried, and failed, in children with Schönlein-Henoch purpura.
2004 Brit. Med. Jrnl. 3 Jan. 25/1 A provisional diagnosis of Schönlein-Henoch purpura due to candesartan was made.
This entry has been updated (OED Third Edition, June 2019; most recently modified version published online March 2022).
<
n.1922